Anti-mutated Citrullinated Vimentin Antibodies Research Articles

Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis

ObjectivesSmoking has been connected to citrullination of antigens and formation of anti-citrullinated peptide antibodies (ACPAs) in rheumatoid arthritis (RA). Since smoking can modify proteins by carbamylation (formation of homocitrulline), this...

Anti-MCV antibodies predict radiographic progression in Greek patients with very early (

This study aimed to assess the diagnostic and prognostic value of anti-mutated citrullinated vimentin (MCV) antibodies in very early rheumatoid arthritis (VERA) and in established rheumatoid arthritis (RA). Seventy-one patients with undifferentiated arthritis (UA) of <3months duration, 141 with established RA, 53 with other rheumatic diseases, and 40 healthy individuals were included in the study. Anti-MCV, anti-cyclic citrullinated peptide (CCP) antibodies, and rheumatoid factor (RF) were determined and hand radiographs were recorded. Patients were assessed prospectively for 2years, and hand radiographs were repeated. Diagnostic performance of anti-MCV was studied with receiver operating characteristic (ROC) curves and evaluation of sensitivity, specificity, and likelihood ratios. Forty-six percent of UA patients progressed to RA at 2years. In VERA patients, sensitivity of anti-MCV was 52%, compared to 44% of anti-CCP and 37% of RF, while specificity was 91%, compared to 91% of RF and 84% of anti-CCP. Anti-MCV were detected in 25% of VERA patients negative for both anti-CCP and RF. In established RA, anti-MCV did not sustain its diagnostic performance. By multivariable analysis, anti-MCV, but not anti-CCP or RF, showed significant correlation with radiographic progression in VERA patients. In established RA, anti-MCV, anti-CCP, and RF were associated with active disease (p≤0.03) and joint damage (p≤0.004). By multivariate analysis, the strongest factors for radiographic damage were disease duration (p=0.000), HAQ score (p=0.000), and RF (p=0.002). In conclusion, in patients with very early UA, anti-MCV predict both progression to RA and radiological damage, and therefore, anti-MCV antibody testing may be useful in every day practice.

Role of anti-mutated citrullinated vimentin antibodies in chronic hepatitis C patients and its relation to HCV associated arthritis

Aim of the workTo determine the frequency of anti-mutated citrullinated vimentin (anti-MCV) antibodies in chronic hepatitis C virus (HCV) patients and its relation to HCV associated arthritis. Patients and methodsThe study included 60 HCV patients and 30age and sex matched control. Patients were subgrouped according to the presence and absence of associated arthritis. Laboratory investigations were performed and anti-MCV antibodies were measured. ResultsThe age of the patients ranged between 29 and 75years (mean 57.65±8.49years) and they were 38 males (63.3%) and 22 females (36.7%) M:F 1.7:1. 32 (53.3%) patients had arthritis while the remaining 28 (46.7%) did not. There was a significantly higher anti-MCV antibody level in the patients (median 250ug/L; range 175–375ug/L) compared to the control (p<0.001). There was no significant difference in the anti-MCV antibodies between HCV patients with and without arthritis (p=0.15). The HCV patients without arthritis had a significantly higher level of anti-MCV antibody (median 200ug/L, range 175–375ug/L) than the control (median 30ug/L, range 5–15ug/L) (p<0.001) and the area under the curve (AUC) was 0.85 (95% CI 0.69–1, p=0.004). When the cut-off value for anti-MCV antibody was set at 57.5ug/L, clinical sensitivity was 80% and specificity was 80% between those without arthritis and the control. There was no significant correlation between anti-MCV antibody with various studied parameters in the HCV patients. ConclusionAnti-MCV antibody is significantly increased in HCV patient and has no role in diagnosing HCV-associated arthritis.

Anti-MCV and anti-CCP antibodies-diagnostic and prognostic value in children with juvenile idiopathic arthritis (JIA).

The goal of the study was to evaluate the diagnostic and prognostic value of anti-mutated citrullinated vimentin (anti-MCV) antibodies in juvenile idiopathic arthritis (JIA) comparing to anti-cyclic citrullinated peptide (anti-CCP). Thirty children with confirmed JIA diagnosis and 20 children as a control group were included into the study. Serum and synovial fluid levels of anti-CCP, anti-MCV, and immunoglobulin M rheumatoid factor (IgM-RF) antibodies have been assessed. Anti-MCV was positive in 11/30 (36.6%), whereas anti-CCP positivity was found in 12/30 (40%) children with JIA. Among 11 children with JIA positive for anti-MCV, five (45.5%) were also positive for anti-CCP and among 18 JIA children negative for anti-CCP, six (33.33%) were also anti-MCV positive. Six out of 30 JIA children were found to be IgM-RF positive. In general, two out of all those 11 anti-MCV-positive patients demonstrated oligoarthritis and 9/11 had polyarticular type of onset. Anti-MCV serum concentration correlated positively with anti-CCP (p=0.004). Almost 60% of children in early stage of JIA were anti-MCV positive. Levels of anti-CCP antibodies correlated positively with the disease activity (p=0.0014) and radiological outcome (p=0.00017). In all synovial fluid samples, the concentration of autoantibodies was under the cut-off values. The results of our study indicate that anti-MCV as well as anti-CCP antibodies may be helpful in the diagnosis of JIA, especially in the early course of the disease. Anti-MCV antibodies could identify a group of children with JIA which is negative for anti-CCP antibodies and RF. However, it appears that in JIA, anti-CCP rather than anti-MCV antibodies have impact on radiographic changes.

Hearing impairment in patients with rheumatoid arthritis: association with anti-citrullinated protein antibodies.

It has been suggested that hearing impairment (HI) is one of the extra-articular features of rheumatoid arthritis (RA). Nevertheless, the prevalence and nature of HI in RA is still uncertain. The objectives were to study hearing function in patients with RA using audiometric tests and to examine whether HI correlates with autoantibodies. Hearing functions were investigated in 43 consecutive RA patients and 23 control subjects (less than 60years old). Their sera were evaluated for the presence of rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and anti-mutated citrullinated vimentin (anti-MCV) antibodies. HI was observed in 46.5% of RA patients and in 30.4% of control subjects, p = 0.32. HI was characterized as sensorineural in 80 and 85.7% of RA patients and control subjects with HI, respectively, p = 1.00. RA patients had a worse hearing threshold for air conduction at 6kHz in the right ear (p = 0.019) and had a decreased amplitude of otoacoustic emissions (OAEs) at 2kHz bilaterally (p = 0.04) compared with control subjects. In the RA group, patients with and without HI were 80 and 34.78% anti-CCP positive, respectively, p = 0.008. RA patients with and without HI were 85 and 43.48% anti-MCV positive, respectively, p = 0.013. HI in RA patients was mainly sensorineural and was associated with anti-CCP and anti-MCV antibodies.

Erratum: Assessment of serum antimutated citrullinated vimentin antibodies in rheumatoid arthritis

Erratum: Assessment of serum antimutated citrullinated vimentin antibodies in rheumatoid arthritis

Anti-mutated citrullinatedvimentin antibody for predicting the activity of rheumatoid arthritis

Anti-mutated citrullinatedvimentin antibody for predicting the activity of rheumatoid arthritis

Assessment of serum antimutated citrullinated vimentin antibodies in rheumatoid arthritis

In the article titled, “Assessment of serum antimutated citrullinated vimentin antibodies in rheumatoid arthritis” published in pages 62–67, Issue 2, Vol. 42 of Egyptian Society for Rheumatology and Rehabilitation[1], the running head of the article is written incorrectly as “Potential role of antimutated citrullinated vimentin antibodies in rheumatoid arthritis” instead of “Assessment of serum antimutated citrullinated vimentin antibodies in rheumatoid arthritis”. This has now been corrected and reposted online.

Pattern of drugs use and association with anti-mutated citrullinated vimentin antibody in rheumatoid arthritis.

Objectives:To demonstrate the pattern of disease-modifying antirheumatic drugs (DMARDs) use in Saudi and non-Saudi rheumatoid arthritis (RA) patients, and to evaluate the association of DMARDs use with anti-mutated citrullinated vimentin (anti-MCV) positivity and other factors.Methods:Retrospectively, for a period of 7 years (2007-2014), we studied 205 RA patients, at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia. All patients used DMARDs. Pattern of use for all 6 DMARDs was almost the same among Saudis and non-Saudis with no significant difference (p>0.05) for each DMARD; MTX was the most commonly used DMARD (71-76%).Results:There was no association between anti-MCV positivity and different DMARDs use. Methotrexate was used 76 times as combination, scoring the highest in this respect. There was a significant correlation (p<0.05) between Plaquenil with Methotrexate and with Sulfasalazine; Leflunomide with anti-TNF and with Prednisolone; age with Methotrexate and with Plaquenil; anti-MCV positivity with Prednisolone. Saudi/non-Saudi status showed no correlation with all factors or drugs. There was no significant association between DMARDs and comorbidity.Conclusion:Similar to worldwide results, MTX was the most commonly used DMARD; with the addition of anti-TNF to increase the effect, and folic acid to minimize the side effects. In this cohort, the pattern of use for all DMARDs was similar among Saudis and non-Saudis; treatment depended neither on anti-MCV positivity nor on the presence of comorbid conditions. A study of the association of DMARDs with disease activity is recommended.

Anti-Mutated Citrullinated Vimentin Antibody and Rheumatoid Factor (Prevalence and Association) in Rheumatoid Arthritis Patients; Saudi and Non-Saudi

background: The aims of this study were to assess the prevalence of anti-mutated citrullinated vimentin (MCV) antibodies and rheumatoid factor (RF) and to evaluate their association in rheumatoid arthritis patients, both Saudi and non-Saudi. Retrospectively, we studied 280 rheumatoid arthritis patients, at King Abdulaziz University Hospital. The antibodies were measured by enzyme linked immunosorbent assay and rheumatoid factor by nephelometry. The 280 patients included 196 Saudis and 84 non-Saudis, 88% females and 12% males, and the mean age was 45.3 years (SD = 14.3). Prevalence of rheumatoid factor was 141/280 (50%) divided as 93/196 (47.5%) Saudis and 48/84 (57%) non-Saudis, with no significant differences (p > 0.05). Prevalence of mutated citrullinated vimentin antibodies was 165/280 (58.2%) divided as 121/196 (61.7%) Saudis and 44/84 (52.4%) non-Saudis, with no significant differences (p > 0.05). Among RF -ve patients, considerable numbers were anti-MCV +ve, and vice versa. Also, among the anti-MCV -ve patients, considerable numbers were RF +ve, and vice versa. In all cohorts and in Saudi and non Saudi patients, anti-MCV positivity was significantly associated with RF positivity (odds ratio (OR) 3.15; 95% CI 1.9, 5.19/p = 0.000); ESR and CRP were high with significant correlation (p < 0.005) with each other, with RF positivity but not with anti-MC positivity. Anti-MC positivity showed no significant correlation with age and gender. In this cohort of patients, anti-MCV antibodies are a useful diagnostic tool for RA, but its combination with RF is essential. Both markers are significantly associated. Larger scale studies are recommended. Correlation of anti-MCV with treatment and with disease activity still has to be published.

Diagnostic value of anti-MCV antibodies for ankylosing spondylitis

Objective To investigate the diagnostic value of anti-mutated citrullinated vimentin（anti-MCV） and anti-cyclic citrullinated peptide（anti-CCP） antibodies for ankylosing spondylitis (AS), and to establish a new diagnostic method of AS based on anti-citrullinated protein/peptide antibodies（ACPAs） detection. Methods Totally 121 AS patients(AS group), 97 rheumatoid arthritis（RA） patients(RA group)and 103 healthy people(control group) were enrolled for the detection of serum levels of anti-MCV and anti-CCP antibodies using ELISA method as a diagnostic test. HLA-B27 in AS patients was tested by flow cytometry, and RF-IgM in RA and AS patients was detected by immune rate nephelometry. Receiver operating characteristics (ROC) curve was used to analyze the diagnostic value and to determine the cut-off value. Anti-MCV and anti-CCP antibodies among each group were compared by Mann-Whitney U test, Chi-square test or Fisher′s exact test was used to compare positive rate. Results The anti-MCV levels in AS group ［11.60 (12.36-25.83) U/ml］were significantly higher than control group ［11.60(8.41-13.54）U/ml ］,U=2 413,P<0.001, while the levels of anti-CCP had no difference between the two groups ［AS group 6.22 （4.30-8.07）U/ml］, and control group ［6.01(3.77-7.58)U/ml］, respectively; U=5 421,P=0.094. The calculated area under the ROC curve of anti-MCV was 0.806,and 14.67 U/ml was the optimal cut-off value with sensitivity of 0.645 and specificity of 0.942. In both HLA-B27 positive and negative AS patients, anti-MCV antibodies levels and positive rate were significantly higher than control group using new cut-off value above （U=133.5, P=0.001; U=2 279.5,P<0.001). Sensitivity of the combination detection of anti-MCV and anti-CCP (MCV+CCP－) or RF-IgM (MCV+RF－) were 60.3% (73/121), 62.8% (76/121) and specificity were 89.7% (87/97), 90.7% (88/97) respectively in differential diagnosis of AS and RA, which were significantly higher than anti-MCV detection alone in specificity (16.5%,16/97). Conclusions Anti-MCV could be a new biomarker for the diagnosis of AS. With high sensitivity and specificity, anti-MCV has an equal diagnostic efficiency in HLA-B27 positive and negative AS patients using our new cut-off value. Additionally， the combination detection of anti-MCV and anti-CCP or RF-IgM could be an effective method for differential diagnosis of AS and RA.（Chin J Lab Med,2014,37: 455-458） Key words: Spondylitis,ankylosing; Peptides,cyclic; Vimentin; Mutation; Rheumatoid factor

AB0284 The Diagnostic Utility of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis

BackgroundAntibodies against citrullinated peptides have gained special importance in the diagnosis of rheumatoid arthritis (RA) (1,2).ObjectivesThis study aims to investigate the diagnostic sensitivity and specificity of anti-mutated citrullinated vimentin (anti-MCV)...

AB0039 The Frequency of Acpa-Specific B Cells in the Circulating Memory B Cell Pool of Patients with Rheumatoid Arthritis

BackgroundRheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by the presence of autoantibodies (AA) such as rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPAs). These AA do not...

PHS7 - The Diagnostic And Clinical Value Of Anti-Mutated Citrullinated Vimentin Antibodies In Rheumatoid Arthritis

PHS7 - The Diagnostic And Clinical Value Of Anti-Mutated Citrullinated Vimentin Antibodies In Rheumatoid Arthritis

Anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis patients: Relation to disease activity and manifestations

Aim of the workTo evaluate the frequency of anti-mutated citrullinated vimentin antibodies (MCV) in rheumatoid arthritis (RA) patients and to correlate it with disease activity and various disease manifestations. Patients and methodsFifty RA patients were recruited from the rheumatology and rehabilitation outpatient clinic, Kasr Al-Aini. Thirty healthy subjects served as controls. All patients were subjected to full history taking and clinical examination including general and joint assessment. Disease activity was assessed by the disease activity score (DAS-28) and functional ability was evaluated by the Modified Health Assessment Questionnaire (MHAQ). Anti-MCV and anti-cyclic citrullinated peptide (anti-CCP) were assayed by ELISA in patients and controls. Plain X-ray was performed on the hands and wrists and Sharp score was used to assess the erosions and joint space narrowing. ResultsA highly significant elevation of serum anti-MCV in RA patients (135.82±126.81U/ml) compared to controls (13.63±8.48U/ml) (p<0.0001) was found. Anti-MCV showed a sensitivity of 84% and specificity of 80%. There was a significant difference between anti-MCV positive and anti-MCV negative patients as regards MHAQ (1.07±0.74 vs. 0.52±0.37, p=0.005) and Sharp erosion score (12.93±23.55 vs. 4±2.2, p=0.02). Anti-CCP showed a sensitivity of 70% and specificity of 100%. There was a significant difference between the specificities of both markers (p=0.03). There was no significant correlation of the anti-MCV with the clinical manifestations, MHAQ, DAS28 or Sharp score. Anti-MCV significantly correlated with anti-CCP (p<0.0001). ConclusionAnti-MCV test has a significant association with the functional disability and radiologic progression in RA and could be considered as a promising biomarker.

Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis.

We evaluated the association between anti-cyclic citrullinated peptide antibodies (anti-CCP) and anti-mutated citrullinated vimentin antibodies (anti-MCV) with the presence of extra-articular (ExRA) manifestations in 225 patients with rheumatoid arthritis (RA). Ninety-five patients had ExRA and 130 had no ExRA. There was no association of anti-CCP and anti-MCV levels with the presence of ExRA as total group (P = 0.40 and P = 0.91, resp.). Making an analysis of individual manifestations, rheumatoid nodules were associated with positivity for rheumatoid factor (RF); (P = 0.01), anti-CCP (P = 0.048), and anti-MCV (P = 0.02). Instead, RF, anti-CCP, or anti-MCV were not associated with SS, chronic anemia, or peripheral neuropathy. Levels of anti-CCP correlated with the score of the Health Assessment Questionnaire-Disability Index (HAQ-Di) (r = 0.154, P = 0.03), erythrocyte sedimentation rate (ESR); (r = 0.155, P = 0.03), and RF (P = 0.254, P < 0.001), whereas anti-MCV titres only correlated with RF (r = 0.169, P = 0.02). On adjusted analysis, ExRA was associated with longer age (P = 0.015), longer disease duration (P = 0.007), higher DAS-28 score (P = 0.002), and higher HAQ-DI score (P = 0.007), but serum levels of anti-CCP and anti-MCV were not associated. These findings show the need to strengthen the evaluation of the pathogenic mechanisms implied in each specific ExRA manifestation.

Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-generation anti-citrullinated cyclic peptides testing.

Determination of anti-citrullinated peptide antibodies (ACPA) plays a relevant role in the diagnosis of rheumatoid arthritis (RA). To date, it is still unclear if the use of several tests for these autoantibodies in the same patient offers additional value as compared to performing only one test. Therefore, we evaluated the performance of using two assays for ACPA: second-generation anti-citrullinated cyclic peptides antibodies (anti-CCP2) and anti-mutated citrullinated vimentin (anti-MCV) antibodies for the diagnosis of RA. We compared three groups: RA (n = 142), chronic inflammatory disease (CIRD, n = 86), and clinically healthy subjects (CHS, n = 56) to evaluate sensitivity, specificity, predictive values, and likelihood ratios (LR) of these two assays for the presence of RA. A lower frequency of positivity for anti-CCP2 was found in RA (66.2%) as compared with anti-MCV (81.0%). When comparing RA versus other CIRD, sensitivity increased when both assays were performed. This strategy of testing both assays had high specificity and LR+. We conclude that adding the assay of anti-MCV antibodies to the determination of anti-CCP2 increases the sensitivity for detecting seropositive RA. Therefore, we propose the use of both assays in the initial screening of RA in longitudinal studies, including early onset of undifferentiated arthritis.

The Diagnostic Utility of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis

The Diagnostic Utility of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis

SAT0098 Seropositivity of anti-cyclic citrullinated peptide antibody is more prevalent in unaffected first-degree relatives with multicases families of rheumatoid arthritis

ObjectivesThis study elucidates the prevalence of seropositivity and determinants for rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and anti-mutated citrullinated vimentin (anti-MCV) antibodies in unaffected first-degree relatives (FDRs) of rheumatoid...

Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients

To evaluate the diagnostic value of anti-mutated citrullinated vimentin antibodies (anti-MCV), anti-cyclic citrullinated peptides antibodies (anti-CCP), anti-glucose-6-phosphate isomerase antibodies (anti-GPI) and anti-keratin antibodies (AKA) and rheumatoid factor (RF) in rheumatoid arthritis (RA). The five auto-antibodies were detected in serum samples of 56 patients with RA, 21 patients with systemic lupus erythematosus (SLE), 11 with ankylosing spondylitis (AS), six with Sjögren's syndrome (SS), four with connective tissue disease (CTD) and 20 healthy controls. Anti-MCV, anti-CCP and anti-GPI were detected by enzyme-linked immunosorbent assays (ELISA), AKA was determined by indirect immunofluorescence and RF was determined by rate nephelometry. In RA, anti-MCV and anti-GPI had the highest sensitivity (78.6% and 75.0%, respectively), anti-CCP and AKA had the highest specificity (97.6%). Anti-GPI had the lowest specificity (64.3%), and AKA had the lowest sensitivity (48.2%). When two antibodies were detected together, the sensitivity of anti-MCV/anti-CCP/RF were highest (92.9%) with a lower specificity (73.8%). The combination of anti-MCV/anti-CCP had a slightly decreased sensitivity (89.3%) and the same specificity (73.8%). The combination RF/anti-MCV/anti-CCP or anti-MCV/anti-CCP are usefully serologic tests for the diagnosis of RA in Chinese patients.